Skip to main content
Equibles

UBS Group AG

Position in ZYME — Zymeworks Inc.

CIK 1610520 ZURICH, V8
Back to ZYME Full portfolio

Position in ZYME

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$3,008,581
-$1,292,764 QoQ
Shares Held
115,095
-33.0% QoQ
Ownership
0.162%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#48
of 202 holders
Holding Since
Dec 2022
15 quarters on record
Voting authority Sole 99% Shared 0% None 1%

Common Shares in ZYME Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,806 across 561 Biotechnology names. ZYME ranks #181 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in ZYME

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,008,581 115,095
2026-03-31 $4,301,345 171,779
2025-12-31 $7,342,225 278,854
2025-09-30 $885,444 51,841
2025-06-30 $3,156,450 251,510
2025-03-31 $2,552,312 214,300
2024-12-31 $2,443,357 166,896
2024-09-30 $1,701,214 135,555
2024-06-30 $1,069,485 125,674
2024-03-31 $709,300 67,424
2023-12-31 $669,261 64,414
2023-09-30 $239,778 37,820
2023-06-30 $262,551 30,388
2023-03-31 $136,196 15,066
2022-12-31 $196 25